Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's

Eisai Co Ltd ESALY and its U.S. partner Biogen Inc's BIIB Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300 American medical institutions.
The treatment is already being administered to some patients, the head of Eisai's neurology business told Nikkei.
Aducanumab received conditional approval from the FDA in June under a cloud of doubts.
The drug targets plaques in the brain formed by amyloid proteins believed to be a significant cause of Alzheimer's-related dementia.
Eisai has identified around 900 U.S. medical centers seen as likely to adopt the treatment.
How many patients actually receive the expensive drug is being closely watched to indicate whether it will reach blockbuster status.
Some medical centers, including Mount Sinai Health System and Cleveland Clinic, have chosen not to use Aduhelm.
Eisai says that medical institutions that initially took a pass on the drug could introduce it later.
Price Action: BIIB shares are up 0.68% at $345.83, while ESALY shares are down 0.33% at $82.48 during the market session on the last check Tuesday.